Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation
Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/9673537 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832548709544493056 |
|---|---|
| author | Marcia L. Moss Dmitry Minond |
| author_facet | Marcia L. Moss Dmitry Minond |
| author_sort | Marcia L. Moss |
| collection | DOAJ |
| description | Since its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation. |
| format | Article |
| id | doaj-art-dfcab54e8f904d6a9e15533358ba6254 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-dfcab54e8f904d6a9e15533358ba62542025-02-03T06:13:21ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/96735379673537Recent Advances in ADAM17 Research: A Promising Target for Cancer and InflammationMarcia L. Moss0Dmitry Minond1Verra Therapeutics, 127 Asbury Rd., Lansing, NY 14882, USARumbaugh-Goodwin Institute for Cancer Research, Nova Southeastern University, 3321 College Avenue, CCR 6th Floor, Fort Lauderdale, FL 33328, USASince its discovery, ADAM17, also known as TNFα converting enzyme or TACE, is now known to process over 80 different substrates. Many of these substrates are mediators of cancer and inflammation. The field of ADAM metalloproteinases is at a crossroad with many of the new potential therapeutic agents for ADAM17 advancing into the clinic. Researchers have now developed potential drugs for ADAM17 that are selective and do not have the side effects which were seen in earlier chemical entities that targeted this enzyme. ADAM17 inhibitors have broad therapeutic potential, with properties ranging from tumor immunosurveillance and overcoming drug and radiation resistance in cancer, as treatments for cardiac hypertrophy and inflammatory conditions such as inflammatory bowel disease and rheumatoid arthritis. This review focuses on substrates and inhibitors identified more recently for ADAM17 and their role in cancer and inflammation.http://dx.doi.org/10.1155/2017/9673537 |
| spellingShingle | Marcia L. Moss Dmitry Minond Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation Mediators of Inflammation |
| title | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation |
| title_full | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation |
| title_fullStr | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation |
| title_full_unstemmed | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation |
| title_short | Recent Advances in ADAM17 Research: A Promising Target for Cancer and Inflammation |
| title_sort | recent advances in adam17 research a promising target for cancer and inflammation |
| url | http://dx.doi.org/10.1155/2017/9673537 |
| work_keys_str_mv | AT marcialmoss recentadvancesinadam17researchapromisingtargetforcancerandinflammation AT dmitryminond recentadvancesinadam17researchapromisingtargetforcancerandinflammation |